Compass Therapeutics, Inc. (CMPX)
NASDAQ:CMPX
Want to see CMPX full AI Analyst Report?
Total Valuation
Compass Therapeutics has a market cap or net worth of $372.78M. The enterprise value is $240.88M.
Market Cap$372.78M
Enterprise Value$240.88M
Share Statistics
Compass Therapeutics has 180,087,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding180,087,920
Owned by Insiders12.74%
Owned by Institutions67.57%
Financial Efficiency
Compass Therapeutics’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -35.25%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-35.25%
Return on Capital Employed (ROCE)-0.35
Revenue Per Employee0.00
Profits Per Employee-1.90M
Employee Count35
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Compass Therapeutics is ―. Compass Therapeutics’s PEG ratio is -0.76.
PE Ratio―
PS Ratio0.00
PB Ratio4.30
Price to Fair Value4.30
Price to FCF-17.22
Price to Operating Cash Flow-7.25
PEG Ratio-0.76
Income Statement
In the last 12 months, Compass Therapeutics had revenue of 0.00 and earned -66.49M in profits. Earnings per share was -0.42.
Revenue0.00
Gross Profit-1.47M
Operating Income-72.84M
Pretax Income-66.49M
Net Income-66.49M
EBITDA-71.37M
Earnings Per Share (EPS)-0.42
Cash Flow
In the last 12 months, operating cash flow was -53.20M and capital expenditures -89.00K, giving a free cash flow of -53.29M billion.
Operating Cash Flow-53.20M
Free Cash Flow-53.29M
Free Cash Flow per Share-0.30
Dividends & Yields
Compass Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.05
52-Week Price Change-1.90%
50-Day Moving Average3.98
200-Day Moving Average4.52
Relative Strength Index (RSI)34.34
Average Volume (3m)12.57M
Important Dates
Compass Therapeutics upcoming earnings date is Aug 5, 2026, Before Open (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateAug 5, 2026
Ex-Dividend Date―
Financial Position
Compass Therapeutics as a current ratio of 15.02, with Debt / Equity ratio of 5.25%
Current Ratio15.02
Quick Ratio15.02
Debt to Market Cap0.01
Net Debt to EBITDA0.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Compass Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Compass Therapeutics EV to EBITDA ratio is -11.57, with an EV/FCF ratio of -16.80.
EV to Sales0.00
EV to EBITDA-11.57
EV to Free Cash Flow-16.80
EV to Operating Cash Flow-16.81
Balance Sheet
Compass Therapeutics has $194.69M in cash and marketable securities with $9.79M in debt, giving a net cash position of $184.90M billion.
Cash & Marketable Securities$194.69M
Total Debt$9.79M
Net Cash$184.90M
Net Cash Per Share$1.03
Tangible Book Value Per Share$1.25
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Compass Therapeutics is $10.11, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.11
Price Target Upside68.52% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast-100.00%
EPS Growth Forecast-2.72%